Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Harvard Business School
Dow
Colorcon
Boehringer Ingelheim
Medtronic
Express Scripts

Last Updated: November 18, 2019

DrugPatentWatch Database Preview

ENBREL Drug Profile

See Plans and Pricing

« Back to Dashboard

Recent Clinical Trials for ENBREL

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Academic Medical Organization of Southwestern OntarioPhase 4
Lawson Health Research InstitutePhase 4
Psoriasis Treatment Center of Central New JerseyPhase 4

See all ENBREL clinical trials

Recent Litigation for ENBREL

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
CELGENE CORPORATION v. HETERO LABS LIMITED2019-07-16
CELGENE CORPORATION v. DR. REDDY'S LABORATORIES, LTD.2019-07-12
CELGENE CORPORATION v. CIPLA LIMITED2019-07-03

See all ENBREL litigation

PTAB Litigation
PetitionerDate
Dr. Reddy's Laboratories, Inc.2018-08-03

See all ENBREL litigation

Pharmacology for ENBREL

Company Disclosures: US Patents for ENBREL

These patents were extracted from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Immunex ENBREL etanercept VIAL; SUBCUTANEOUS 103795 001 1998-11-02   Start Trial Immunex Corporation (Seattle, WA) 2012-03-07 RX Orphan company
Immunex ENBREL etanercept VIAL; SUBCUTANEOUS 103795 001 1998-11-02   Start Trial Immunex Corporation (Seattle, WA) 2014-02-25 RX Orphan company
Immunex ENBREL etanercept VIAL; SUBCUTANEOUS 103795 001 1998-11-02   Start Trial Immunex Corporation (Seattle, WA) 2009-09-05 RX Orphan company
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Patent Text Search: US Patents for ENBREL

These patents were identified by searching patent claims

Supplementary Protection Certificates for ENBREL

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
CA 2015 00021 Denmark   Start Trial PRODUCT NAME: IBRUTINIB ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/14/945 20141021
92692 Luxembourg   Start Trial PRODUCT NAME: IBRUTINIB, OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI. FIRST REGISTRATION: 20141023
PA2008014 Lithuania   Start Trial PRODUCT NAME: ABATACEPTUM; REGISTRATION NO/DATE: EU/1/07/389/001, 2007 05 21, EU/1/07/389/002, 2007 05 21, EU/1/07/389/003 20070521
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
McKinsey
Johnson and Johnson
Baxter
Mallinckrodt
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.